PCSK9 and atherosclerosis: Carriers of loss-of-function mutations in the PCSK9 gene were found to have 28% lower LDL-C, accompanied by 88% reduced risk of coronary artery disease (CAD), making PCSK9 a promising treatment target for ASCVD prevention (Cohen et al., 2006).